Hot off the press #AMG193 in MTAP deleted cancers!! A potentially impactful treatment for patients with advanced MTAP loss cancer Amgen Oncology HKU Medicine ESMO - Eur. Oncology

⭐️Wow ! Blown away by the phenomenal discussion on MTAP & PRMT5 inhibitors by Cigall Kadoch Dana-Farber Toni Choueiri, MD ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors

Hans Prenen #ESMO24 concomitant paper: Adrian Sacher, M.D. presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium Hans Prenen

It’s just incredible to be part of this community of talented and supportive colleagues in #HongKong #esmoasia2024 ESMO - Eur. Oncology

Thank you ESMO - Eur. Oncology for the invite and my honor to contribute ! And so happy to work with a great GU team! Ravindran Kanesvaran Roberto Iacovelli Elena Castro Renu Eapen Ignacio Duran Marniza

Looking forward to seeing everyone in #HongKong at #ESMOTATAsia25

📢 Just published in Annals of Oncology: “ESMO Precision Oncology Working Group Recommendations on the Structure and Quality Indicators for Molecular Tumour Boards in Clinical Practice”. sciencedirect.com/science/articl… Ben Westphalen ESMO - Eur. Oncology

Thank you to all the investigators for their extraordinary efforts in shaping the MTB consensus statements. 🙌 Under the outstanding leadership of G Curigliano MD PhD and Ben Westphalen, this collaborative achievement sets a new benchmark for the field🚀 Bravo to the entire team!

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice. Discover the key focus areas to optimise #PrecisionOncology Read via #ESMODailyReporter: ow.ly/mexL50VvtUM Ben Westphalen Annals of Oncology

📣 Join us in Hong Kong for a chance to contribute to oncology drug development in Asia Pacific! ⏰ Late registration deadline: 18 June 🔗 ow.ly/MWyG50W90Ef Herbert Loong, MBBS, FASCO Tony Mok Ben Tran Aya Helali MD PhD

Hot off the press! Our commentary exploring the potential of Adv-mSS, a dual-targeting oncolytic adenovirus. This innovation supercharges TAMs and CD8 T-cells, delivering a one-two punch to cancer. HKU Medicine Journal for ImmunoTherapy of Cancer Marc Lecoultre jitc.bmj.com/content/13/6/e…

Thanks RTHK for giving me the opportunity to #introduce and #discuss #SoftTissue #sarcomas to the wider community. A group of #rarediseases which benefits from #awareness and #specialistcare #sarcomaawarenessmonth #CUHKSarcoma CUHK Medicine CTOS #CTOSTweeTOS

RTHK CUHK Medicine CTOS Also had the opportunity to highlight our CUHK Medicine HKU Medicine study that was published in ESMO - Eur. Oncology ESMO Open some years ago look at #comorbidities of patients w/ #sarcomas. We have identified that 10% of #newly diagnosed #sarcoma patients in #hongkong had #DiabetesMellitus,

Prof Aya Helali MD PhD -precautions/pitfalls in reporting exploratory biomarker analyses (No single guideline addresses this); Prof Herbert Loong, MBBS, FASCO increasing importance of PROs in early phase clin trials incl dose esc decisions-it’s complicated! #ESMOTATAsia25 ESMO - Eur. Oncology

What an absolute pleasure to share that stage with you all at #WCLC25 IASLC Montse Sanchez-Cespedes Lab Guilherme Harada Maraver Lab Triparna Sen (Sen-Lab) 💫

Just back from #ESMO25! 🧠⚡️ Latest in #glioma Rx: - SCOUT trial’s “watch-and-see” #NTRK inhibitor approach (challenge: when to pause?) - IL13Ra2 #CART cells – progress but TME/antigen escape hurdles - Procaspase 3: apoptosis revival? 🔥 #NeuroOncology HKU Medicine ESMO - Eur. Oncology

Thx Enes Erul MD for spotlighting #ISLB2025's stakeholder discussions! Key takeaways: the integration of AI may revolutionise liquid biopsy, integrating multi-omics for real-time tumor tracking and treatment modification. #PrecisionMedicine #MRD #liquidbiopsy HKU Medicine